Design Therapeutics, Inc.

NASDAQ:DSGN

Biotechnology

Healthcare
$9.47 +1.59%

+$0.19 today

Market cap
$606.42M
Beta
1.66
P/E (TTM)
-10.7
EPS (TTM)
-$1.13
52W Low $3.33High $17.25

Volume 0.32M

Average 0.74M

DSGN Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Design Therapeutics, Inc.NASDAQ: DSGN

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses declines year over year

Q1 FY2026 other income / expenses of $2.07M fell 23.4% year over year, ahead of the -25.9% change in trailing-twelve-month other income / expenses. Sequentially, it fell 4.7% from the prior quarter. Over 3 fiscal years it compounded at +31.2% a year.

Context

  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -23.4% holds above the trailing-twelve-month pace of -25.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.07M-4.7% QoQ
Last fiscal yearDec 2025
$9.68M-24.4% YoY
LTMMar 2026
$9.04M-25.9% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.4%——
1 year-24.4%——
3-year CAGR+31.2%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
9.68M USD
Year-over-year change
-24.4%
4-year CAGR
+138.7%

Other Income / Expenses vs competitors

How DSGN compares with its peers on the latest reported figures

  • DSGN's LTM Mar 2026 other income / expenses of $9.04M is the 7th highest of the 11 companies compared; the peer median is $11.86M.
  • Its year-over-year change of -25.9% is the 7th highest of 11, against a peer median of -6.8%.
  • Over three fiscal years its annual growth of +31.2% compares with a peer median of +57.6%.
DSGN Competitors Peer median
Other Income / Expenses for DSGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$65.43M +239.3%—3.0%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$21.61M +11.8%-76.4%2.3%
DYNDyne Therapeutics, Inc.LTM Jun 2026$17.55M -37.4%+97.2%—
STOKStoke Therapeutics, Inc.LTM Mar 2026$14.2M +6.7%+60.9%44.3%
WVEWave Life Sciences Ltd.LTM Mar 2026$13.29M -1.0%+91.1%18.5%
FULCFulcrum Therapeutics, Inc.LTM Mar 2026$10.44M -12.7%+54.3%—
DSGNDesign Therapeutics, Inc.LTM Mar 2026$9.04M -25.9%+31.2%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$6.42M -36.5%+80.0%—
SLDBSolid Biosciences Inc.LTM Mar 2026$4.68M +44.4%-38.0%—
PEPGPepGen Inc.LTM Mar 2026$4.08M -37.0%+11.3%—
PTCTPTC Therapeutics, Inc.LTM Jun 2026-$183.33M -250.6%—18.2%
Peer median (excluding DSGN) $11.86M-6.8%+57.6%18.2%

Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0466K537K596K622K
Gross Profit0(466K)(537K)(596K)(622K)
Gross Margin—————
Research & Development24.78M48.61M57.06M44.35M59.13M
Selling, General & Admin11.05M18.98M21.13M18.03M20.34M
Operating Expenses35.83M67.13M77.65M61.79M78.85M
Depreciation & Amortization129K466K537K596K622K
EBITDA(35.4M)(62.84M)(66.33M)(48.99M)(69.17M)
EBITDA Margin—————
Operating Income(35.83M)(67.59M)(78.19M)(62.38M)(79.47M)
Operating Margin—————
Interest Income00012.8M9.68M
Interest Expense00000
Other Income / Expenses298K4.29M11.33M12.8M9.68M
Income Before Tax(35.53M)(63.31M)(66.86M)(49.59M)(69.79M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(35.53M)(63.31M)(66.86M)(49.59M)(69.79M)
Net Margin—————
EPS (Basic)(0.77)(1.14)(1.19)(0.88)(1.22)
EPS (Diluted)(0.77)(1.14)(1.19)(0.88)(1.22)
Weighted Avg Shares45.94M55.71M55.98M56.59M57.33M
Weighted Avg Shares (Diluted)45.94M55.71M55.98M56.59M57.33M

Design Therapeutics, Inc.

NASDAQ:DSGN

Intrinsic Alpha fair value

Locked

Current Price

$9.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.